| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 110.6 | 90.1 | 87.1 |
| Other income | 0.6 | 1.9 | 0.5 |
| Total income | 111.2 | 91.9 | 87.7 |
| Profit before exceptional items & tax | 13.1 | 10.1 | 8.0 |
| Profit before tax | 13.1 | 10.1 | 8.0 |
| Net profit | 9.8 | 7.3 | 6.0 |
| Operating margin | 11.8% | 11.0% | 9.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +63.30% |
|---|---|
| Net profit, quarter on quarter | +34.20% |
| Revenue, year on year | +27.00% |
NSE results filing, NSE: SATKARTAR. Figures extracted from the filing.
Sat Kartar Life Ltd: key numbers
- Share price
- ₹187.70
- Market cap
- ₹296.5 Cr
- Revenue (annual)
- ₹200.7 Cr
- Net profit (annual)
- ₹17.10 Cr
- P/E (TTM)
- 17.3×Sector 50.4×
- Promoter holding
- 63.62%
- FII holding
- 0.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sat Kartar Life Ltd
All →Sat Kartar Life Capacity Expansion: ₹0.7 Cr Investment
Sat Kartar Life signed an LOI for a 20-bed hospital-cum-therapy centre in Dehradun at ₹0.70 Crore. The facility is expected to be operational by December 2026.
- Value
- ₹0.70 Cr
- Execution
- by 15 December 2026
- hospital bed capacity
- 20 beds
Sat Kartar Life Earnings Call: Key Takeaways
Sat Kartar Life reported 23% revenue growth crossing ₹200cr in FY26. Transitioning from product-focused to an integrated Ayurvedic healthcare ecosystem including hospitals.
Sat Kartar Life Earnings Call: Key Takeaways
Sat Kartar Life transitioned from a product-focused entity to a healthcare ecosystem, delivering record growth in FY26. Management is aggressively targeting 150% revenue growth by FY28 through massive hospital bed expansion and US market entry.